Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

被引：29
作者：
Jamil, Muhammad O. [1 ]
Mehta, Amitkumar [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Hematol & Oncol, 1720 2nd Ave South,NP2540N, Birmingham, AL 35294 USA
来源：
EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 05期
关键词：
Diffuse large B cell lymphoma; Prognostic marker; lenalidomide; ibrutinib; brentuximab vedotin; bortezomib; POSITRON-EMISSION-TOMOGRAPHY; CHOP-LIKE CHEMOTHERAPY; R-CHOP; MYC REARRANGEMENTS; MOLECULAR SUBTYPES; BURKITT-LYMPHOMA; ELDERLY-PATIENTS; POOR-PROGNOSIS; YOUNG-PATIENTS; OPEN-LABEL;
D O I：
10.1586/17474086.2016.1146584
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma (NHL). DLBCL is clinically, pathologically and molecularly heterogeneous disease. Various clinical, pathological and molecular markers have been developed to characterize the disease. Based on these characterizations, new targeted agents are being investigated to optimize the treatment and improve the outcomes of DLBCL. Enhanced molecular understanding, invention of targeted agents and immunotherapy has opened the doors for improvement in the treatment of DLBCL. In this review, we will discuss various prognostic markers of DLBCL and their potential therapeutic implications.
引用
收藏
页码：471 / 477
页数：7
相关论文
共 77 条
[1]   MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP [J].
Alencar, Alvaro J. ;
Malumbres, Raquel ;
Kozloski, Goldi A. ;
Advani, Ranjana ;
Talreja, Neha ;
Chinichian, Shideh ;
Briones, Javier ;
Natkunam, Yasodha ;
Sehn, Laurie H. ;
Gascoyne, Randy D. ;
Tibshirani, Rob ;
Lossos, Izidore S. .
CLINICAL CANCER RESEARCH, 2011, 17 (12) :4125-4135
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]  
[Anonymous], 2014, CLIN ADV HEMATOL ONC, V12, P18
[4]   Thalidomide analogues as anticancer drugs [J].
Aragon-Ching, Jeanny B. ;
Li, Haiqing ;
Gardner, Erin R. ;
Figg, William D. .
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (02) :167-174
[5]   Double-hit B-cell lymphomas [J].
Aukema, Sietse M. ;
Siebert, Reiner ;
Schuuring, Ed ;
van Imhoff, Gustaaf W. ;
Kluin-Nelemans, Hanneke C. ;
Boerma, Evert-Jan ;
Kluin, Philip M. .
BLOOD, 2011, 117 (08) :2319-2331
[6]   Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].
Barrans, Sharon ;
Crouch, Simon ;
Smith, Alex ;
Turner, Kathryn ;
Owen, Roger ;
Patmore, Russell ;
Roman, Eve ;
Jack, Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365
[7]   CD30: seeing is not always believing [J].
Blum, Kristie A. .
BLOOD, 2015, 125 (09) :1358-1359
[8]   Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma [J].
Broyde, Adi ;
Boycov, Olga ;
Strenov, Yulia ;
Okon, Elimelech ;
Shpilberg, Ofer ;
Bairey, Osnat .
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (06) :338-343
[9]   HIV-associated lymphomas and gamma-herpesviruses [J].
Carbone, Antonino ;
Cesarman, Ethel ;
Spina, Michele ;
Gloghini, Annunziata ;
Schulz, Thomas F. .
BLOOD, 2009, 113 (06) :1213-1224
[10]  
Chan WC, 1997, BLOOD, V89, P3909
12345678